drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cells)
drug_description
Autologous T cells genetically engineered to express chimeric antigen receptors that recognize CLL1 (CLEC12A) and CD38 on AML cells, enabling antigen-dependent T-cell activation and cytotoxic killing independent of the native TCR; designed to broaden AML coverage and reduce antigen escape.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are genetically engineered to express chimeric antigen receptors that recognize CLL1 (CLEC12A) and CD38 on AML cells. Antigen binding triggers CAR signaling (CD3ΞΆ with costimulatory domains) independent of the native TCR, leading to T-cell activation, proliferation, cytokine release, and perforin/granzyme-mediated cytotoxic killing of AML blasts and leukemic stem/progenitor cells. Dual targeting is intended to broaden AML coverage and reduce antigen escape.
drug_name
CLL1/CD38 dual-target CAR-T cells (autologous)
nct_id_drug_ref
NCT06110208